Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure
PharmaShots
APRIL 25, 2023
This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. Founded Year: 2012 Total Employees: ~190 Headquarters: California, United States Market Cap: $1.2B It is a subcutaneous RNAi therapeutic designed to reduce HBV viral antigens, including HBsAg.
Let's personalize your content